Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | LMNA | P02545 | 5/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | PGR | P06401 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | PDE4A | P27815 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | HRH1 | P35367 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4318446 | 0.84 | CYP1A2 (0.47) | POLBALDH1A1LMNACYP1A2CYP2D6 | |
| SCHEMBL3914676 | 0.82 | LMNA (0.57) | POLBALDH1A1LMNACYP1A2CYP2D6 | |
| SCHEMBL14373762 | 0.82 | ALDH1A1 (0.51) | POLBALDH1A1LMNACYP1A2CYP2D6 | |
| SCHEMBL4307584 | 0.82 | MTNR1A (0.57) | POLBALDH1A1LMNACYP1A2CYP2D6 | |
| SCHEMBL13612573 | 0.81 | ALDH1A1 (0.58) | POLBALDH1A1LMNACYP1A2CYP2D6 | |
| SCHEMBL4196096 | 0.80 | MAPT (0.56) | ALDH1A1LMNACYP1A2CYP2C19HPGD | |
| SCHEMBL3917768 | 0.78 | MTNR1A (0.55) | POLBALDH1A1LMNACYP1A2CYP2D6 | |
| SCHEMBL4317050 | 0.75 | MTNR1A (0.59) | POLBALDH1A1LMNACYP1A2CYP2D6 | |
| SCHEMBL13612579 | 0.74 | CYP1A2 (0.56) | POLBALDH1A1LMNACYP1A2CYP2D6 | |
| SCHEMBL14373766 | 0.74 | ALDH1A1 (0.50) | POLBALDH1A1LMNACYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090281154-A1 | Ophthalmic Compositions for Treating Ocular Hypertension | MERCK SHARP & DOHME CORP. | 2009-11-12 | — | — | US | claimed |
| US-20090281154-A1 | Ophthalmic Compositions for Treating Ocular Hypertension | MERCK SHARP & DOHME CORP. | 2009-11-12 | — | — | US | disclosed |
| US-20090281154-A1 | Ophthalmic Compositions for Treating Ocular Hypertension | MERCK SHARP & DOHME CORP. | 2009-11-12 | — | — | US | disclosed |
| US-20090281154-A1 | Ophthalmic Compositions for Treating Ocular Hypertension | MERCK SHARP & DOHME CORP. | 2009-11-12 | — | — | US | disclosed |
| EP-2032130-A2 | OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION | Merck & Co., Inc. (US) | 2009-03-11 | — | — | EP | disclosed |
| WO-2007146136-A2 | OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION | MERCK & CO., INC. (US) | 2007-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281154-A1 | Ophthalmic Compositions for Treating Ocular Hypertension | KCNN1, KCNN3, KCNN2 | POLB 3704/4885ALDH1A1 1796/4885LMNA 315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.